Latest Market News

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

Ingenia Communities Group has reported a robust FY25 performance, exceeding underlying EPS guidance with a 33% increase and signalling strong momentum heading into FY26.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.

Kip McGrath Education Centres announces a one-year on-market share buy-back of up to 10% of its shares, aiming to enhance shareholder value amid strong cash reserves and profitability forecasts.

Corporate Travel Management Limited has delayed its FY25 financial results due to potential revenue recognition adjustments in Europe, prompting a voluntary ASX trading suspension.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Tribeca Global Natural Resources Limited (ASX – TGF) has declared a fully franked 5-cent dividend for FY25 alongside a 10% on-market buyback, while delivering returns that outpaced major natural resource indices. The company’s portfolio is well positioned to benefit from rising strategic demand for critical and precious metals amid evolving global market dynamics.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.